Pfizer considers purchase of India's Agila Specialties - report
REUTERS - Pfizer Inc is considering buying India's Agila Specialties, the injectable-medicines unit of Indian drug supplier Strides Arcolab Ltd (STAR.NS), for a possible price of $2 billion, Bloomberg reported on Monday.
Pfizer is doing due diligence and a deal could be reached this quarter, Bloomberg reported, citing unnamed sources.
A Pfizer spokeswoman said the company does not comment on market rumours or speculation.
Agila makes cancer treatments and antibiotics, Bloomberg said.
Pfizer shares were up 23 cents at $26.75 on the New York Stock Exchange. (Reporting By Caroline Humer; editing by John Wallace)
- Tweet this
- Share this
- Digg this
- Nine reasons why India's WTO veto shocked the world
- India says WTO deal not dead, can sign in Sept if concerns addressed
- India's demands block $1 trillion WTO deal on customs rules
- Nifty falls most in nearly 3-1/2 weeks; Sensex down over 400 points
- In cat-and-mouse game, India uncovers new gold smuggling route
U.S. Secretary of State John Kerry told Prime Minister Narendra Modi on Friday that India's refusal to sign a global trade deal sent the wrong signal, and he urged New Delhi to work to resolve the row as soon as possible. Read | India block $1 trillion WTO deal